Page 30 - Patrick Wingrove News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Moderna Inc on Thursday raised its annual forecast for COVID-19 vaccine sales to up to $8 billion on hopes of a boost in the fall season as sales move to a private market in the United States from government contracts, sending its shares up 6% in premarket trading. COVID vaccine makers Moderna and Pfizer are pinning their hopes on private markets sales and strong demand for their new updated shots targeting XBB.1.5 variant to turn around a slump in sales of the products that had bumper growth during the peak of the pandemic. Moderna expects $6 billion to $8 billion in sales from its COVID sh...

Moderna Inc on Thursday raised its annual forecast for COVID-19 vaccine sales to up to $8 billion on hopes of a boost in the fall season as sales move to a private market in the United States from...

Teva Pharmaceutical Industries will still pursue launching a biosimilar of AbbVie's blockbuster arthritis drug Humira next year despite a crowded marketplace, Chief Executive Richard Francis said on...

By Steven Scheer JERUSALEM (Reuters) -Teva Pharmaceutical Industries will still pursue launching a biosimilar of AbbVie's blockbuster arthritis drug Humira ...

Injectable versions of some widely-used cancer drugs including Johnson & Johnson's blockbuster multiple myeloma treatment Darzalex are likely to be excluded from new U.S. government price negotiations for years, drugmakers told Reuters, protecting billions in revenue. J&J, Merck & Co, which is testing an injectable version of its top-selling immunotherapy Keytruda, and Halozyme Therapeutics, which licenses the critical new ingredient, hyaluronidase, for subcutaneous drugs, all told Reuters they believe the reformulation qualifies the medicines to be treated like new drugs....